FindTrial
Sign In

Intravitreal Ozurdex for Recurrent Vogt-Koyanagi-Harada

Intravitreal Dexamethasone implant in Recurrent Vogt-Koyanagi-Harada

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040167
Enrollment
20
Registered
2022-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H308- Other chorioretinal inflammations

Interventions

Intervention1: Intravitreal injection of Ozurdex: sustained-release dexamethasone implant (Ozudex)in eyes of Vogt-Koyanagi-Harada Control Intervention1: NA: NA

Sponsors

L V Prasad Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cases of VKH, who come back with recurrence

Exclusion criteria

Exclusion criteria: patients on steroids and immunosuppresants

Design outcomes

Primary

MeasureTime frame
Resolution of inflammationTimepoint: 1, 2 and 4 months—

Secondary

MeasureTime frame
Any complication like elevated IOPTimepoint: 1, 2 and 4 months—

Countries

India

Contacts

Public ContactDrMudit Tyagi

L V Prasad Eye Institute

drmudit@lvpei.org09553339042

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026